淋巴瘤使用利妥昔单抗期间的不良反应分析

Aualysis of Adverse Reactions During the Use of Rituximab for Lymphoma

目的总结淋巴瘤治疗中采用利妥昔单抗注射液期间的不良反应,指导临床用药。方法回顾性分析我院2019年5月~2023年12月收治的B细胞淋巴瘤患者109例,统计本组患者的不良反应发生情况。结果(1)在109例病例中,弥漫大B细胞淋巴瘤患者最多,占64.22%;(2)从利妥昔单抗注射液治疗方案来看,利妥昔单抗单独使用22例,占比20.18%,联合用药方案87例,占79.82%。联合用药方案中R-CHOP方案(O主要为多柔比星或者柔红霉素)达64.22%;(3)从利妥昔单抗注射液不良反应累及系统或器官来看,血液系统不良反应最多,共60例,占55.04%,其次是消化系统44例,占40.37%。(4)利妥昔单抗注射液血液系统不良反应Ⅱ度最高,共30例,占50.00%;消化系统不良反应Ⅰ度最高,占63.63%。结论在采用利妥昔单抗注射液治疗淋巴瘤时,患者可能出现多种不良反应,对此应规范用药管理,尽量预防和减少不良反应。

OBJECTIVE To summarize the adverse reactions during the use of rituximab injection in the treatment of lymphoma and guide clinical medication.METHODS A retrospective analysis was conducted on 109 patients with B-cell lymphoma admitted to our hospital from May 2019 to December 2023,and the incidence of adverse reactions in this group of patients was statistically analyzed.RESULTS(1)Among the 109 cases,diffuse large B-cell lymphoma patients were the most common,accounting for 64.22%;(2)From the treatment plan of rituximab injection,22 cases were treated with rituximab alone,accounting for 20.18%,and 87 cases were treated with combination therapy,accounting for 79.82%.The R-CHOP regimen(mainly Doxorubicin or Doxorubicin)in the combination therapy regimen accounts for 64.22%;(3)From the perspective of adverse reactions involving the system or organs caused by rituximab injection,the hematological system had the most adverse reactions,with a total of 60 cases,accounting for 55.04%,followed by the digestive system with 44 cases,accounting for 40.37%.(4)Rituximab injection had the highest grade II adverse reactions in the blood system,with a total of 30 cases,accounting for 50.00%;The degree of adverse reactions in the digestive system is the highest,accounting for 63.63%.CONCLUSION When using rituximab injection to treat lymphoma,patients may experience various adverse reactions.Therefore,medication management should be standardized to prevent and reduce adverse reactions as much as possible.